XML 14 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 24,684 $ 34,591
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation 4,213 12,406
Depreciation and amortization 11,289 11,910
Assets write-down 1,110 1,143
Changes in value of life insurance policies (3,188) (3,221)
Deferred income taxes 102 (14,757)
Gain on insurance recovery for damage to property, plant and equipment (2,102) 0
Other non-cash items 1,478 300
Changes in assets and liabilities:    
Accounts receivable (9,461) 2,872
Inventories 6,212 (14,614)
Prepaid expenses and other current assets (4,357) (3,902)
Other assets (205) 1,711
Accounts payable (373) (13,101)
Accrued expenses 2,392 (3,924)
Unearned revenues 2,453 (1,306)
Other liabilities 1,526 (4,748)
Net cash provided by operating activities 35,773 5,360
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital expenditures (8,647) (7,843)
Patents and other intangibles 0 (158)
Proceeds from sale of assets 934 420
Net proceeds from insurance recovery 2,102 0
Net proceeds on life insurance policies 2,776 3,375
Net cash used in investing activities (2,835) (4,206)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Repayment of long-term debt (62,000) (184,000)
Proceeds from long-term debt 38,000 190,000
Debt issuance costs 0 (1,251)
Dividends paid (1,407) (1,401)
Repurchase of common stock (402) (418)
Equity related transaction costs (756) (2,842)
Other financing activities (19) (54)
Net cash provided by (used in) financing activities (26,584) 34
NET CHANGE IN CASH AND CASH EQUIVALENTS 6,354 1,188
CASH AND CASH EQUIVALENTS, beginning of period 15,120 15,428
CASH AND CASH EQUIVALENTS, end of period 21,474 16,616
Supplemental disclosures of cash flow information:    
Cash payments for interest 8,741 8,341
Cash payments for income taxes 11,892 16,013
Non-cash investing and financing activities:    
Capital expenditures incurred but not paid for as of the end of the period 1,591 1,039
Equity related transaction costs incurred but not paid for as of the end of the period $ 0 $ 1,724